Related Experiment Video

Updated: May 27, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Norcantharidin induces melanoma cell apoptosis through activation of TR3 dependent pathway

Shujing Liu1, Hong Yu, Suresh M Kumar

  • 1Department of Pathology, University of Pennsylvania School of Medicine, Philadelphia, USA.

Cancer Biology & Therapy
|November 30, 2011
PubMed

Insights

Norcantharidin (NCTD) inhibits melanoma growth by inducing cancer cell apoptosis. This occurs through a TR3-dependent pathway, suggesting NCTD as a potential melanoma therapeutic agent.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Norcantharidin (NCTD) exhibits antitumor properties, but its mechanism in melanoma is unclear.
  • TR3 expression is reduced in metastatic melanomas and linked to apoptosis.
  • Understanding NCTD's action is crucial for developing effective melanoma treatments.

Purpose of the Study:

  • To elucidate the mechanism of NCTD's antitumor effect in melanoma.
  • To investigate the role of TR3 in NCTD-induced melanoma cell apoptosis.
  • To evaluate NCTD's efficacy in a preclinical melanoma mouse model.

Main Methods:

  • Melanoma cell proliferation and apoptosis assays were performed.
  • TR3 translocation, mitochondrial changes, and protein expression (Bax, Bcl-2, caspase-3, NF-κB2) were analyzed.
  • TR3 knockdown and in vivo studies in transgenic melanoma mouse models were conducted.

Main Results:

  • NCTD inhibited melanoma cell proliferation and induced apoptosis dose-dependently.
  • NCTD promoted TR3 nuclear-to-mitochondrial translocation, co-localizing with Bcl-2.
  • NCTD increased cytochrome c release, Bax, and cleaved caspase-3, while decreasing Bcl-2 and NF-κB2.
  • TR3 knockdown abrogated NCTD's effects.
  • NCTD reduced tumor volume and improved survival in mice.

Conclusions:

  • NCTD induces melanoma cell apoptosis via a TR3-dependent pathway.
  • TR3 plays a critical role in mediating NCTD's anti-melanoma effects.
  • NCTD demonstrates potential as a therapeutic agent for melanoma.

More Related Videos

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression11:02

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression

Published on: August 3, 2011

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate (DMBA-TPA)04:12

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate (DMBA-TPA)

Published on: December 19, 2019

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...